Literature DB >> 3314368

The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets.

B Rama1, T Mandel, J Jansen, E Dingeldein, H D Mennel.   

Abstract

In an experimental glioma model, using ethylnitrosourea induced and subsequently intracerebrally implanted tumours in BD-IX rats, the effectiveness of intratumoural application of methotrexate (MTX) by stereotactic implantation of polymethylmethacrylate (PMMA) pellets containing MTX, has been studied. Tumour volume 10 days after pellet implantation as well as survival rates of treated, untreated and control animals have been the criteria of the effect of treatment. Tumour volume was significantly smaller in treated compared to untreated animals. The survival rate of untreated to treated animals increased 150 and 233% respectively when compared with the control animals. Thus a positive therapeutic effect of MTX-PMMA pellet implantation in the experimental glioma could be proven. Possible consequences for the treatment of human gliomas are shortly discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314368     DOI: 10.1007/BF02076020

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  41 in total

1.  Study of effectiveness of bleomycin in rat brain tumor model intravenously and intracerebrally.

Authors:  T S Vats; R A Morantz; G W Wood; S Tilzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

2.  Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents.

Authors:  R Ringkjob
Journal:  Acta Neurol Scand       Date:  1968       Impact factor: 3.209

3.  Treatment of malignant brain tumors by local methotrexate. A preliminary report.

Authors:  S R Weiss; R Raskind
Journal:  Int Surg       Date:  1969-02

4.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

5.  Chemotherapy in intracerebrally transplanted tumors induced with transplacental administration of ethylnitrosourea in rats.

Authors:  H D Mennel; D Hellwig; H Simon
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

6.  Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.

Authors:  M A Gerosa; D V Dougherty; C B Wilson; M L Rosenblum
Journal:  J Neurosurg       Date:  1983-03       Impact factor: 5.115

7.  Therapy of an experimental glioma with systemic or intraneoplastic methotrexate or radiation.

Authors:  C H Tator; W Wassenaar; A Day; W S So
Journal:  J Neurosurg       Date:  1977-02       Impact factor: 5.115

8.  Regional blood flow and capillary permeability in the ethylnitrosourea-induced rat glioma.

Authors:  K Yamada; T Hayakawa; Y Ushio; N Arita; A Kato; H Mogami
Journal:  J Neurosurg       Date:  1981-12       Impact factor: 5.115

9.  Current brain tumour models with particular consideration of the transplantation techniques. Outline of literature and personal preliminary results.

Authors:  B Rama; O Spoerri; M Holzgraefe; H D Mennel
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

10.  Blood flow and regulation of blood flow in experimental peritumoral edema.

Authors:  K A Hossman; M Blöink
Journal:  Stroke       Date:  1981 Mar-Apr       Impact factor: 7.914

View more
  3 in total

Review 1.  Distribution of drugs following controlled delivery to the brain interstitium.

Authors:  M Mak; L Fung; J F Strasser; W M Saltzman
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

Review 2.  Interstitial chemotherapy for brain tumors: review.

Authors:  T Tomita
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

3.  Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.

Authors:  Y Takada; N H Greig; D T Vistica; S I Rapoport; Q R Smith
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.